Atrial Fibrillation Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,850	143 Pages	Fortune Business Insights Pvt. Ltd.	November, 2024	FOB19302825

Best Price Guarantee
Price	from $4,850
Length	143 Pages
Publisher	Fortune Business Insights Pvt. Ltd.
Published Date	November, 2024
SKU	FOB19302825

Atrial Fibrillation Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Growth Factors of Atrial Fibrillation Market

The Atrial Fibrillation Market size was valued at USD 15.21 billion in 2022 and is projected to grow from USD 15.85 billion in 2023 to USD 21.47 billion by 2030, exhibiting a CAGR of 4.4% during the forecast period of 2024-2032.

The COVID-19 pandemic disrupted the atrial fibrillation (AF) market as hospitals prioritized vital care for COVID patients, suspending optional techniques like catheter ablation. Lockdowns additionally delayed patient diagnosis and observe-up care, lowering call for for AF remedies. However, the pandemic expanded telemedicine adoption, allowing faraway monitoring of heart conditions, which helped mitigate a few disruptions. As healthcare systems normalize, the backlog of processes and developing awareness of heart-associated complications put up-COVID have begun riding marketplace recovery. Additionally, the expanded focus on cardiovascular health after the pandemic is predicted to gas the call for for innovative AF therapies.

A key fashion within the AF marketplace is the rising adoption of minimally invasive strategies, specifically cryoablation and radiofrequency ablation. These techniques are gaining popularity due to the fact they provide faster recovery instances, lower hassle prices, and improved affected person consequences as compared to conventional surgical approaches. Companies are actively making an investment in superior catheters and imaging technologies to beautify the precision of those procedures. Furthermore, wearable devices for non-stop cardiac monitoring are rising as a trend, helping patients and healthcare providers locate arrhythmias early, control dangers higher, and optimize treatment.

The growing international occurrence of atrial fibrillation, particularly amongst getting old populations, is a number one motive force of market growth. As life expectancy rises, age-related situations like AF have become more not unusual, creating a full-size demand for effective treatments. Additionally, way of life-related factors which includes weight problems, hypertension, and diabetes make a contribution to the growing AF burden. Governments and healthcare organizations are also promoting early diagnosis through screening programs and focus campaigns, further using the demand for AF control solutions. The aggregate of those elements is predicted to propel the marketplace over the coming years.

Comprehensive Analysis of Atrial Fibrillation Market

The Atrial Fibrillation Market growth is rising at an exponential rate due to its marketplace segmentation. This market expansion correctly affords a detailed local assessments thinking about the dominant supply and call for forces that effect the enterprise. These segmentations are methodically segregated by drug class, by route of administration, by distribution channel. By Drug Class include Anticoagulants, Antiarrhythmic Drugs. By Route of Administration include Oral, Intravenous, Others. By Distribution Channel include Hospital Pharmacies, Online Pharmacies, Retail Pharmacies.

The North America location lead the Atrial Fibrillation Market share percentage via benefitting a marketplace size of USD 5.95 billion The rising prevalence of atrial fibrillation in the region, along with the availability of a conducive environment for developing and seeking approval for new drugs, are some factors driving the adoption of these drugs in the region.

The top players in the market play a crucial role in the industry assuring market growth and setting market standards. These players include, Google LLC (Alphabet, Inc.), Magic Leap, Inc., ReWalk Robotics, SAMSUNG, B-Temia, Panasonic Holdings Corporation, NVIDIA Corporation, Microsoft, Ekso Bionics, Vuzix,these market players provide a level-playing competitive landscape.

November 2023: Bayer AG accelerated its segment three medical trial program for the investigational drug asundexian. The corporation is investigating the drug as a capacity remedy in patients affected by atrial fibrillation with a high threat of stroke or embolism.

Segmentation Table

ATTRIBUTE DETAILS

Study Period 2019-2030

Base Year 2022

Estimated Year 2023

Forecast Period 2023-2030

Historical Period 2019-2021

Growth Rate CAGR of 4.4% from 2023-2030

Unit Value (USD Billion)

Segmentation By Drug Class

Anticoagulants

Antiarrhythmic Drugs

By Route of Administration

Oral

Intravenous

Others

By Distribution Channel

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

By Region

North America (By Drug Class, Route of Administration, Distribution Channel, and Country)

U.S.

Canada

Europe (By Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)

U.K.

Germany

France

Spain

Italy

Scandinavia

Rest of Europe

Asia Pacific (By Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)

China

India

Japan

Australia

Southeast Asia

Rest of Asia Pacific

Latin America (By Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)

Brazil

Mexico

Rest of Latin America

Middle East & Africa (By Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)

GCC

South Africa

Rest of the Middle East & Africa

Please Note: It will take 5-6 business days to complete the report upon order confirmation.

1. Introduction: 1.1. Research Scope; 1.2. Market Segmentation; 1.3. Research Methodology; 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics: 3.1. Market Drivers; 3.2. Market Restraints; 3.3. Market Opportunities; 3.4. Market Trends
4. Key Insights: 4.1. Prevalence of Rheumatoid Arthritis & Psoriasis – For Key Countries; 4.2. Pipeline Analysis; 4.3. Patent Snapshot; 4.4. New Product Launches; 4.5. Key Industry Developments - Mergers, Acquisitions and Partnerships
5. Global Anti-inflammatory Biologics Market Analysis, Insights and Forecast, 2022-2030: 5.1. Market Analysis, Insights and Forecast – By Drug Class; 5.1.1. Anti-Tumor Necrosis Factor (TNF); 5.1.2. Interleukin Antagonists; 5.1.3. Janus Kinase (JAK) Inhibitors; 5.1.4. Others; 5.2. Market Analysis, Insights and Forecast – By Application; 5.2.1. Rheumatoid Arthritis; 5.2.2. Psoriasis; 5.2.3. Others; 5.3. Market Analysis, Insights and Forecast – By Route of Administration; 5.3.1. Oral; 5.3.2. Injection; 5.3.2.1. Subcutaneous; 5.3.2.2. Intravenous; 5.4. Market Analysis, Insights and Forecast – By Distribution Channel; 5.4.1. Hospital Pharmacy; 5.4.2. Retail Pharmacy; 5.4.3. Online Pharmacy; 5.5. Market Analysis, Insights and Forecast – By Region; 5.5.1. North America; 5.5.2. Europe; 5.5.3. Asia Pacific; 5.5.4. Latin America; 5.5.5. Middle East & Africa
6. North America Anti-inflammatory Biologics Market Analysis, Insights and Forecast, 2022-2030: 6.1. Market Analysis, Insights and Forecast – By Drug Class; 6.1.1. Anti-Tumor Necrosis Factor (TNF); 6.1.2. Interleukin Antagonists; 6.1.3. Janus Kinase (JAK) Inhibitors; 6.1.4. Others; 6.2. Market Analysis, Insights and Forecast – By Application; 6.2.1. Rheumatoid Arthritis; 6.2.2. Psoriasis; 6.2.3. Others; 6.3. Market Analysis, Insights and Forecast – By Route of Administration; 6.3.1. Oral; 6.3.2. Injection; 6.3.2.1. Subcutaneous; 6.3.2.2. Intravenous; 6.4. Market Analysis, Insights and Forecast – By Distribution Channel; 6.4.1. Hospital Pharmacy; 6.4.2. Retail Pharmacy; 6.4.3. Online Pharmacy; 6.5. Market Analysis, Insights and Forecast – By Country; 6.5.1. U.S.; 6.5.2. Canada
7. Europe Anti-inflammatory Biologics Market Analysis, Insights and Forecast, 2022-2030: 7.1. Market Analysis, Insights and Forecast – By Drug Class; 7.1.1. Anti-Tumor Necrosis Factor (TNF); 7.1.2. Interleukin Antagonists; 7.1.3. Janus Kinase (JAK) Inhibitors; 7.1.4. Others; 7.2. Market Analysis, Insights and Forecast – By Application; 7.2.1. Rheumatoid Arthritis; 7.2.2. Psoriasis; 7.2.3. Others; 7.3. Market Analysis, Insights and Forecast – By Route of Administration; 7.3.1. Oral; 7.3.2. Injection; 7.3.2.1. Subcutaneous; 7.3.2.2. Intravenous; 7.4. Market Analysis, Insights and Forecast – By Distribution Channel; 7.4.1. Hospital Pharmacy; 7.4.2. Retail Pharmacy; 7.4.3. Online Pharmacy; 7.5. Market Analysis, Insights and Forecast – By Countries/ Sub-region; 7.5.1. U.K.; 7.5.2. Germany; 7.5.3. France; 7.5.4. Spain; 7.5.5. Italy; 7.5.6. Scandinavia; 7.5.7. Rest of Europe
8. Asia Pacific Anti-inflammatory Biologics Market Analysis, Insights and Forecast, 2022-2030: 8.1. Market Analysis, Insights and Forecast – By Drug Class; 8.1.1. Anti-Tumor Necrosis Factor (TNF); 8.1.2. Interleukin Antagonists; 8.1.3. Janus Kinase (JAK) Inhibitors; 8.1.4. Others; 8.2. Market Analysis, Insights and Forecast – By Application; 8.2.1. Rheumatoid Arthritis; 8.2.2. Psoriasis; 8.2.3. Others; 8.3. Market Analysis, Insights and Forecast – By Route of Administration; 8.3.1. Oral; 8.3.2. Injection; 8.3.2.1. Subcutaneous; 8.3.2.2. Intravenous; 8.4. Market Analysis, Insights and Forecast – By Distribution Channel; 8.4.1. Hospital Pharmacy; 8.4.2. Retail Pharmacy; 8.4.3. Online Pharmacy; 8.5. Market Analysis, Insights and Forecast – By Countries/ Sub-region; 8.5.1. Japan; 8.5.2. China; 8.5.3. India; 8.5.4. Australia; 8.5.5. Southeast Asia; 8.5.6. Rest of Asia Pacific
9. Latin America Anti-inflammatory Biologics Market Analysis, Insights and Forecast, 2022-2030: 9.1. Market Analysis, Insights and Forecast – By Drug Class; 9.1.1. Anti-Tumor Necrosis Factor (TNF); 9.1.2. Interleukin Antagonists; 9.1.3. Janus Kinase (JAK) Inhibitors; 9.1.4. Others; 9.2. Market Analysis, Insights and Forecast – By Application; 9.2.1. Rheumatoid Arthritis; 9.2.2. Psoriasis; 9.2.3. Others; 9.3. Market Analysis, Insights and Forecast – By Route of Administration; 9.3.1. Oral; 9.3.2. Injection; 9.3.2.1. Subcutaneous; 9.3.2.2. Intravenous; 9.4. Market Analysis, Insights and Forecast – By Distribution Channel; 9.4.1. Hospital Pharmacy; 9.4.2. Retail Pharmacy; 9.4.3. Online Pharmacy; 9.5. Market Analysis, Insights and Forecast – By Countries/ Sub regions; 9.5.1. Brazil; 9.5.2. Mexico; 9.5.3. Rest of Latin America
10. Middle East & Africa Anti-inflammatory Biologics Market Analysis, Insights and Forecast, 2022-2030: 10.1. Market Analysis, Insights and Forecast – By Drug Class; 10.1.1. Anti-Tumor Necrosis Factor (TNF); 10.1.2. Interleukin Antagonists; 10.1.3. Janus Kinase (JAK) Inhibitors; 10.1.4. Others; 10.2. Market Analysis, Insights and Forecast – By Application; 10.2.1. Rheumatoid Arthritis; 10.2.2. Psoriasis; 10.2.3. Others; 10.3. Market Analysis, Insights and Forecast – By Route of Administration; 10.3.1. Oral; 10.3.2. Injection; 10.3.2.1. Subcutaneous; 10.3.2.2. Intravenous; 10.4. Market Analysis, Insights and Forecast – By Distribution Channel; 10.4.1. Hospital Pharmacy; 10.4.2. Retail Pharmacy; 10.4.3. Online Pharmacy; 10.5. Market Analysis, Insights and Forecast – By Countries/ Sub region; 10.5.1. South Africa; 10.5.2. GCC; 10.5.3. Rest of Middle East & Africa
11. Competitive Analysis: 11.1. Global Market Share Analysis (2022); 11.2. Company Profiles; 11.2.1. AbbVie Inc.; 11.2.1.1. Overview; 11.2.1.2. Products; 11.2.1.3. SWOT analysis; 11.2.1.4. Recent developments; 11.2.1.5. strategies; 11.2.1.6. financials (based on availability); 11.2.2. Johnson & Johnson Services, Inc.; 11.2.2.1. Overview; 11.2.2.2. Products; 11.2.2.3. SWOT analysis; 11.2.2.4. Recent developments; 11.2.2.5. strategies; 11.2.2.6. financials (based on availability); 11.2.3. Bristol-Myers Squibb Company; 11.2.3.1. Overview; 11.2.3.2. Products; 11.2.3.3. SWOT analysis; 11.2.3.4. Recent developments; 11.2.3.5. strategies; 11.2.3.6. financials (based on availability); 11.2.4. Merck & Co., Inc.; 11.2.4.1. Overview; 11.2.4.2. Products; 11.2.4.3. SWOT analysis; 11.2.4.4. Recent developments; 11.2.4.5. strategies; 11.2.4.6. financials (based on availability); 11.2.5. Pfizer Inc.; 11.2.5.1. Overview; 11.2.5.2. Products; 11.2.5.3. SWOT analysis; 11.2.5.4. Recent developments; 11.2.5.5. strategies; 11.2.5.6. financials (based on availability); 11.2.6. Novartis AG; 11.2.6.1. Overview; 11.2.6.2. Products; 11.2.6.3. SWOT analysis; 11.2.6.4. Recent developments; 11.2.6.5. strategies; 11.2.6.6. financials (based on availability); 11.2.7. UCB S.A.; 11.2.7.1. Overview; 11.2.7.2. Products; 11.2.7.3. SWOT analysis; 11.2.7.4. Recent developments; 11.2.7.5. strategies; 11.2.7.6. financials (based on availability); 11.2.8. Eli Lilly and Company; 11.2.8.1. Overview; 11.2.8.2. Products; 11.2.8.3. SWOT analysis; 11.2.8.4. Recent developments; 11.2.8.5. strategies; 11.2.8.6. financials (based on availability); 11.2.9. Amgen Inc.; 11.2.9.1. Overview; 11.2.9.2. Products; 11.2.9.3. SWOT analysis; 11.2.9.4. Recent developments; 11.2.9.5. strategies; 11.2.9.6. financials (based on availability); 11.2.10. Biogen; 11.2.10.1. Overview; 11.2.10.2. Products; 11.2.10.3. SWOT analysis; 11.2.10.4. Recent developments; 11.2.10.5. strategies; 11.2.10.6. financials (based on availability)